China's medical device innovation makes breakthrough

A clinical study has showcased the remarkable performance of the "J-VALVE Transfemoral (TF) Aortic Valve System", which was jointly developed by Chinese researchers and a domestic medical device company, in improving heart function.

The clinical study of the system, researched by the cardiac surgery team at Zhongshan Hospital in Shanghai and produced by Suzhou Jiecheng Medical Technology Co, was unveiled at the EuroPCR, the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in Paris, France, on May 20 to 23.

This achievement signifies a breakthrough for China in the predominantly import-dominated high-end medical device market.

The 12-month clinical follow-up revealed that patients treated with the "J-VALVE TF Aortic Valve System" had a postoperative all-cause mortality rate of 3.2 percent and a permanent pacemaker implantation rate of 12.6 percent, both leading globally.

The majority of clinical patients were able to get out of bed the day after surgery, significantly reducing the burden on patients, hospitals, and society as a whole.

This collaborative effort between medical professionals and medical experts not only showcases China's advancements in medical technology but also underscores the importance of innovation and continuous improvement in the healthcare sector. The success of the J-VALVE TF Aortic Valve System represents a significant milestone in the development of cutting-edge medical devices in China, with far-reaching implications for patient care and healthcare systems globally.